Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

medicalsciencelaboratoryportraitbeautiful260nw1922200124
September 9th, 2022

Pharmaxis Repurposes PXS-4728 for Parkinson's Disease

Since Boehringer Ingelheim returned the Pharmaxis (PXS: $0.076) drug candidate PXS-4728 in 2020, Pharmaxis has been seeking to find a new indication to trial for the compound, given the level of development work that had been carried out on the compound by Boehringer.

patrys
September 9th, 2022

Patrys Passes Final Manufacturing Tests for PAT-DX1

Patrys' (PAB: $0.024) lead drug antibody drug candidate, PAT-DX1, has passed the final manufacturing assessment meeting all of the specification requirements. This allows Patrys to move into final preclinical toxicology testing ahead of the first clinical study planned for the second half of 2023.

anteris
September 9th, 2022

Anteris Technologies to Present Key Data at TCT this Month

Anteris Technologies (AVR: $21.50) presented at the inaugural E&P Healthcare conference this week.

CEO Wayne Paterson believes that the technical risk for the company's novel aortic valve, the DurAVR 3D, has been significantly diminished, down to only 5%-10% following successful implantation into 13 patients. The remaining risk for the company relates primarily to execution.

Anteris is developing a single piece aortic valve that is implanted via catheter, rather than open-chest surgery.

1583067293163
September 9th, 2022

Patrys Passes Final Manufacturing Tests for PAT-DX1

Patrys' (PAB: $0.024) lead drug antibody drug candidate, PAT-DX1, has passed the final manufacturing assessment meeting all of the specification requirements. This allows Patrys to move into final preclinical toxicology testing ahead of the first clinical study planned for the second half of 2023.

opthea
August 19th, 2022

Opthea – Novel Funding to Access US$260 Million

Opthea (OPT: $1.25) has gained access of up to US$260 million ($371 million) to reach top-line results of two Phase III trials with its drug candidate OPT-302. The top-line results are now due in mid 2024. The funds will also be used for pre-commercialisation activities.

It's the largest capital raise for the sector (excluding raises conducted by CSL, Cochlear and ResMed), for non-asset purchases.

100606173_1405035539698081_2891171799536500736_n
August 19th, 2022

Anteris Technologies to Move to Pivotal Study as Positive Results Continue

For the six and 12 months to 30 June this year, medical device company Anteris Technologies (AVR: $24.60) has been the best performing stock, with a share price gain of 122% over the last six months and 310% over the financial year.

20210629pxs
August 5th, 2022

Pharmaxis Sells Orbital Technology for US$5 Million

Pharmaxis (PXS: $0.077) has executed a deal for the license and sale of its Orbital drug inhalation device with Aptar Pharma for US$5 million.

neuren
August 5th, 2022

Neuren Pharmaceuticals - Partner Files Trofinetide for US Approval

Neuren Pharmaceuticals (NEU: $5.45) has some very clear objectives set for the next 17 months. The most significant of these is gaining US approval of its lead drug candidate, trofinetide, which is being commercialised in North America under license from Neuren by Acadia Pharmaceuticals for the treatment of Rett syndrome in children and adults.

Acadia filed trofinetide for approval last month. The next stage is notice from the FDA that the application is in order and has been accepted (in September), which will trigger a US$10 million payment to Neuren from Acadia.

Imricor_Bug_2020
August 5th, 2022

Imricor - Europe the Key Focus

Imricor Medical Systems (IMR: $0.29) is pioneering MRI-guided cardiac ablation, rather than ablation procedures conducted using x-ray fluoroscopy imaging. It is the only company in the world that sells MRI-compatible consumable devices used for cardiac ablation.

Cardiac ablation is a minimally invasive procedure whereby electrical abnormalities in the heart, which cause abnormal heart rhythms, are corrected by heating or freezing cardiac tissue inside the heart via a catheter. The issue with using x-ray to help guide the procedures is that the heart is almost invisible to x-rays.

vbn
August 5th, 2022

Aroa Biosurgery - Cash Receipts up 162% for Quarter to NZ$13.9 Million

Wound healing products company Aroa Biosurgery (ARX: $0.86) continues to deliver consistent and strong top-line growth. Cash receipts in the June quarter were NZ$13.9 million (up 162% over the PCP). Net cash outflow was NZ$1.3 million from operations and investment in equipment, down from NZ$3.7 million in the PCP and down from NZ$6.5 million in the previous quarter.

Pages